Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population

Nausicaa Malissen; Laetitia Ninove; Xavier de Lamballerie; Nicolas André; Caroline Gaudy-Marqueste

doi:10.1016/j.ejca.2021.07.040

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population

Nausicaa Malissen
, Laetitia Ninove
, Xavier de Lamballerie
, Nicolas André
, Caroline Gaudy-Marqueste

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	125-126
Number of pages	2
Journal	European Journal of Cancer
Volume	156
DOIs	https://doi.org/10.1016/j.ejca.2021.07.040
State	Published - Oct 2021
Externally published	Yes

Access to Document

10.1016/j.ejca.2021.07.040

Cite this

@article{ea24fc67322a4ec5a56a5eaf1c47ae62,

title = "Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population",

author = "Nausicaa Malissen and Laetitia Ninove and \{de Lamballerie\}, Xavier and Nicolas Andr{\'e} and Caroline Gaudy-Marqueste",

note = "Funding Information: N.A. reports receiving grants and drugs for a trial from Bristol Myers Squibb; receiving drugs for a trial from Pierre Fabre; receiving drugs and grants for a clinical trial from Bristol Myers Squibb outside the area of work commented on here; receiving travel support from Bristol Myers Squibb for an International Society of Paediatric Oncology meeting and participating as a scientific advisory board member (without receiving personal fees) for Bayer, Bristol Myers Squibb and Partner Therapeutics outside the area of work commented on here.",

year = "2021",

month = oct,

doi = "10.1016/j.ejca.2021.07.040",

language = "English",

volume = "156",

pages = "125--126",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population

AU - Malissen, Nausicaa

AU - Ninove, Laetitia

AU - de Lamballerie, Xavier

AU - André, Nicolas

AU - Gaudy-Marqueste, Caroline

N1 - Funding Information: N.A. reports receiving grants and drugs for a trial from Bristol Myers Squibb; receiving drugs for a trial from Pierre Fabre; receiving drugs and grants for a clinical trial from Bristol Myers Squibb outside the area of work commented on here; receiving travel support from Bristol Myers Squibb for an International Society of Paediatric Oncology meeting and participating as a scientific advisory board member (without receiving personal fees) for Bayer, Bristol Myers Squibb and Partner Therapeutics outside the area of work commented on here.

PY - 2021/10

Y1 - 2021/10

UR - https://www.scopus.com/pages/publications/85113315845

U2 - 10.1016/j.ejca.2021.07.040

DO - 10.1016/j.ejca.2021.07.040

M3 - Letter

C2 - 34438245

AN - SCOPUS:85113315845

SN - 0959-8049

VL - 156

SP - 125

EP - 126

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -